Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - PEPPER (PEPPER)

July 28, 2022 updated by: University Hospital, Angers

Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Randomised Controlled Trial

This study evaluates the efficacy, in terms of energy expenditure, physical activity level, quality of life, blood pressure, waist circumference and weight, of a general practice based intervention involving a personalised physical exercise medical prescription, the structured delivery of information on the benefits of physical activity, a pedometer, and a pedometer log book, in 35 to 74 year old patients with cardiovascular risks factors.

Study Overview

Detailed Description

Background: Health benefits of physical activity have been shown to be at least as important as drug therapies in the prevention of cardiovascular diseases in patients with hypertension, hyperlipidaemia or diabetes. However, few strategies have demonstrated efficacy and practicality in the promotion of physical exercise among these high risk patients in general practice.

The PEPPER clinical study is a pragmatic randomised trial over a period of 12 months to evaluate the efficacy, in terms of physical activity level, of an intervention based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks, in 35 to 74 year old patients with cardiovascular risks factors. This strategy will be compared to the commonly used oral recommendation of physical activity. The primary outcome is the change in total energy expenditure measured by accelerometry over a 7-day period. Secondary outcomes include changes in physical activity levels (International Physical Activity Questionnaire), quality of life (SF-36), blood pressure, weight, waist circumference, perceived obstacles to physical activity, and patient and doctors compliance with the suggested strategy. 140 patients will be recruited and followed up in 15 GP practices. Measures will be assessed at baseline, at 3 months and at 12 months (end of intervention).

The results of the PEPPER study are expected at the end of 2016. If the intervention proves effective in increasing durably the level of physical activity, this relatively simple and cheap strategy could help decrease the occurrence of cardiovascular events in a large high-risk population seen in general practice.

Study Type

Interventional

Enrollment (Actual)

126

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Angers, France, 49933
        • Angers University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 74 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients consulting their general practitioner for a non-urgent matter
  • with regular follow-up every 3 months for hypertension, hypercholesterolaemia or non insulin dependent type 2 diabetes.
  • judged insufficiently active by their general practitioner based on negative answers to the questions : "Do you practice a physical activity or cycling more than an hour per week?" and "Does your occupation involve physical exertion?"

Exclusion Criteria:

  • contraindication to moderate physical activity,
  • non autonomous for walking,
  • with cognitive or psychiatric impairment limiting the full understanding of the study,
  • suffering from another limiting disease (coronary insufficiency, chronic cardiac failure, etc),
  • who don't speak French,
  • refusing to participate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention PPIL
Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
Other Names:
  • Prescription, Pedometer, Information, Logbook
Active Comparator: Control OR
Oral recommendation of physical exercise delivered by the family doctor.
Other Names:
  • Oral recommendation of physical exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in total energy expenditure by accelerometry at 3 months compared to baseline
Time Frame: baseline and 12 weeks
The total energy expenditure is measured with a wGT3x-BT Actigraph accelerometer worn at the belt during 7 consecutive days from morning to evening. It is measured in Metabolic Equivalent Task-Minutes per Week.
baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in total energy expenditure by accelerometry at 12 months compared to baseline
Time Frame: baseline and 52 weeks
The total energy expenditure is measured with a wGT3x-BT Actigraph accelerometer worn at the belt during 7 consecutive days from morning to evening. It is measured in Metabolic Equivalent Task-Minutes per Week.
baseline and 52 weeks
Change in total energy expenditure by questionnaire at 3 months compared to baseline
Time Frame: baseline and 12 weeks
The total energy expenditure is calculated with the self-administered International Physical Activity Questionaire (IPAQ) short version covering the past 7 days. It is expressed in Metabolic Equivalent Task-Minutes per Week.
baseline and 12 weeks
Change in total energy expenditure by questionnaire at 12 months compared to baseline
Time Frame: baseline and 52 weeks
The total energy expenditure is calculated with the self-administered International Physical Activity Questionaire (IPAQ) short version covering the past 7 days. It is expressed in Metabolic Equivalent Task-Minutes per Week.
baseline and 52 weeks
Change in quality of life at 3 months compared to baseline
Time Frame: baseline and 12 weeks
Change in quality of life as measured by the self-administered Short Form 36 questionnaire
baseline and 12 weeks
Change in quality of life at 12 months compared to baseline
Time Frame: baseline and 52 weeks
Change in quality of life as measured by the self-administered Short Form 36 questionnaire
baseline and 52 weeks
Change in waist circumference at 3 months compared to baseline
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Change in waist circumference at 12 months compared to baseline
Time Frame: baseline and 52 weeks
baseline and 52 weeks
Change in weight at 3 months compared to baseline
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Change in weight at 12 months compared to baseline
Time Frame: baseline and 52 weeks
baseline and 52 weeks
Change in arterial blood pressure at 3 months compared to baseline
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Change in arterial blood pressure at 12 months compared to baseline
Time Frame: baseline and 52 weeks
baseline and 52 weeks
Perceived obstacles to physical exercise
Time Frame: 52 weeks
Perceived obstacles to physical exercise as measured by the Determinant of Physical Activity Questionnaire (DPAQ)
52 weeks
Adherence of doctors and patients to the suggested strategy
Time Frame: 12 weeks
12 weeks
Adherence of doctors and patients to the suggested strategy
Time Frame: 52 weeks
52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Denise Jolivot, MD, University Hospital, Angers
  • Principal Investigator: Laurent Connan, MD, Medical School, Angers

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 16, 2015

Primary Completion (Actual)

August 1, 2018

Study Completion (Actual)

August 1, 2018

Study Registration Dates

First Submitted

December 10, 2014

First Submitted That Met QC Criteria

December 12, 2014

First Posted (Estimate)

December 15, 2014

Study Record Updates

Last Update Posted (Actual)

August 2, 2022

Last Update Submitted That Met QC Criteria

July 28, 2022

Last Verified

August 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Intervention PPIL

3
Subscribe